ISIS: Summary for Isis Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 1:33am EST - Canadian Markets open in 7 hours and 57 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Isis Pharmaceuticals, Inc. (ISIS)

On Feb 9: 11.04 USD

0.04 (0.36%)

MORE ON ISIS

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Isis Pharmaceuticals, Inc. (NasdaqNM:ISIS) Delayed quote data

After Hours: 11.00

0.04 (0.36%) as of 8:01pm EST on 02/09/10

Last Trade:	11.04 USD
Trade Time:	Feb 9
Change:	0.04 (0.36%)
Prev Close:	11.00
Open:	11.12
Bid:	10.49 x 100
Ask:	11.76 x 100
1y Target Est:	20.44

Day's Range:	10.97 - 11.24
52wk Range:	9.77 - 18.81
Volume:	693,619
Avg Vol (3m):	1,431,610
Market Cap:	1.09B
P/E (ttm):	6.83
EPS (ttm):	1.62
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add ISIS to Portfolio

Download Data

HEADLINES

•	10 Biotech Stocks on Clinical Trials Watch
	at TheStreet.com (Thu, Feb 4)

•	Isis Pharmaceuticals Exercises Warrants of iCo Therapeutics Inc.
	CNW Group (Fri, Jan 29)

•	Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
	Business Wire (Mon, Jan 25)

•	Isis Expands Pipeline
	Zacks.com (Mon, Jan 18)

•	Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
	Business Wire (Fri, Jan 15)

•	These 5 Underdogs Are No Dogs
	at Motley Fool (Wed, Jan 13)

•	Dream Stocks for Contrarian Investors
	at Motley Fool (Tue, Jan 12)

•	Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
	Business Wire (Mon, Jan 11)

•	Isis Pharmaceuticals Adds New Cardiovascular Drug to Development Pipeline
	PRNewswire (Mon, Jan 11)

•	3 Stocks in a Tailspin
	at Motley Fool (Thu, Jan 7)

•	Isis Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
	PRNewswire (Wed, Jan 6)

More Headlines for ISIS...

ANALYST

EPS Est (next year) (Dec-09) :	1.51
EPS Est (in 2 years) (Dec-10) :	-0.33
Avg Rec (current)*:	1.9
PEG Ratio:	0.24

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology.

Full Company Profile

Add to Portfolio

Email to a Friend

•